{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "38-year-old male smoker presented with stage 4, cT1bN3M1b, NSCLC adenocarcinoma.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C34",
              "label": "Non-small cell lung cancer",
              "status": "active"
            },
            {
              "code": "C402188",
              "label": "adenocarcinoma",
              "status": "active"
            }
          ],
          "social_history": [
            {
              "category": "smoking",
              "status": "current",
              "description": "38-year-old male smoker"
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Initial biopsy from the mediastinal lymph node showed an EGFR exon 19 deletion using real-time polymerase chain reaction.",
        "clinical_data": {
          "labs": [
            {
              "test": "Polymerase Chain Reaction",
              "value": "EGFR exon 19 deletion",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            }
          ],
          "diagnoses": [
            {
              "code": null,
              "label": "EGFR exon 19 deletion",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Afatinib was administered as a first-line treatment and showed very good partial response with 7.1 months of progression-free survival.",
        "clinical_data": {
          "medications": [
            {
              "drug": "Afatinib",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "Second biopsy from the newly progressed metastatic lymph node showed acquired EGFRT790M mutation.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0597469",
              "label": "EGFR T790M Mutation",
              "status": "active"
            }
          ],
          "procedures": [
            {
              "name": "Biopsy",
              "location": "Lymph Node",
              "outcome": "Positive for EGFRT790M mutation"
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "Patient received lazertinib as a part of a clinical trial (NCT03046992, YH25448-201) and had a partial response for 6.2 months.",
        "clinical_data": {
          "medications": [
            {
              "drug": "lazertinib",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ],
          "procedures": [
            {
              "name": "clinical trial",
              "approach": null,
              "date": null,
              "location": null,
              "performed_by": null,
              "outcome": "partial response"
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "Patient developed malignant ascites. Deep-targeted sequencing of ascites samples demonstrated acquired EGFRC797S mutation in cis (VAF 9.4%), EGFRT790M (VAF 3.5%), and EGFR exon 19 deletion (VAF 9.2%). Patient-derived cells (PDCs) established from the ascites sample showed EGFR exon 19 deletion.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0376395",
              "label": "Malignant ascites",
              "status": "active"
            }
          ],
          "labs": [
            {
              "test": "EGFRC797S mutation",
              "value": "9.4%",
              "unit": "VAF",
              "flag": "abnormal"
            },
            {
              "test": "EGFRT790M",
              "value": "3.5%",
              "unit": "VAF",
              "flag": "abnormal"
            },
            {
              "test": "EGFR exon 19 deletion",
              "value": "9.2%",
              "unit": "VAF",
              "flag": "abnormal"
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Initial diagnostic workup to determine the specific EGFR mutation."
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Treatment initiated based on the EGFR exon 19 deletion.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0001672"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Disease progression and subsequent biopsy to identify resistance mechanisms.",
        "transition_event": {
          "trigger_type": "progression",
          "trigger_entities": [
            "C0009402"
          ],
          "change_type": "progression",
          "target_domain": "diagnosis"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Enrollment in a clinical trial with lazertinib due to acquired EGFRT790M mutation.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0000007"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Development of malignant ascites and identification of EGFRC797S mutation.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [
            "C0376395"
          ],
          "change_type": "progression",
          "target_domain": "symptom"
        }
      }
    }
  ]
}